hapabapa/iStock Editorial via Getty Images Pharma giant Amgen (NASDAQ:AMGN) said on Thursday it had appointed James Bradner as executive vice president, research and development, and chief scientific officer. According to AMGN, Bradner served as president of the Novartis Institutes for BioMedical Research, where he was a member of the executive committee of Novartis (NVS).

hapabapa/iStock通过Getty Images制药巨头安进（NASDAQ:AMGN）发表的社论周四表示，已任命詹姆斯·布拉德纳（JamesBradner）为研发执行副总裁兼首席科学官。据AMGN称，布拉德纳曾任诺华生物医学研究所（Novartis Institutes for BioMedical Research）院长，并曾任诺华执行委员会（NVS）成员。

Bradner succeeds David Reese, who has been named executive vice president and chief technology officer. Reese joined AMGN in 2005 and has led the R&D organization since 2018, the company added. Press Release More on Amgen Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript) AbbVie Vs.

Bradner接替DavidReese，后者被任命为执行副总裁兼首席技术官。Reese于2005年加入AMGN，自2018年以来一直领导研发机构，该公司补充道。有关安进安进公司（AMGN）的新闻稿更多信息，请参阅第六届Evercore ISI HealthCONx年会（成绩单）AbbVie Vs。

Amgen: How Peter Lynch Picks Dividend Stocks Amgen: Buy In Stable Fundamental And Technical Price Growth Amgen gets FDA priority review for small cell lung cancer drug Amgen upgraded at RBC on catalyst setup and growth drivers .

安进：彼得·林奇如何挑选股息股票安进：买入稳定的基本面和技术价格增长安进获得FDA优先审查的小细胞肺癌药物安进在RBC升级的催化剂设置和增长驱动因素。